TABLE 2.
Characteristics of the trials included in the SQ-LNS IPD meta-analyses1
| Infant SQ-LNSs | ||||||
|---|---|---|---|---|---|---|
| Country | Study (reference) | Trial name | Age at start, mo | Duration, mo | Maternal LNSs | Participants |
| Bangladesh | Christian 2015 (41) | JiVitA-4 | 6 | 12 | N | 4218 |
| Bangladesh | Dewey 2017 (42) | RDNS | 6 | 18 | Y/N | 2478 |
| Bangladesh | Luby 2018 (31) | WASH-Benefits-Bangladesh | 6 | 18 | N | 4633 |
| Burkina Faso | Hess 2015 (43) | iLiNS-ZINC | 9 | 9 | N | 2626 |
| Burkina Faso | Becquey 2019 (36) | PROMIS-Burkina Faso | 6 | 12 | N | 2651 |
| Ghana | Adu-Afarwuah 2007 (29) | 6 | 6 | N | 194 | |
| Ghana | Adu-Afarwuah 2016 (44) | iLiNS-DYAD-Ghana | 6 | 12 | Y | 1040 |
| Haiti | Iannotti 2014 (45) | 6–11 | 3–6 | N | 300 | |
| Kenya | Null 2018 (32) | WASH-Benefits-Kenya | 6 | 18 | N | 6649 |
| Madagascar | Galasso 2019 (46) | MAHAY | 6–11 | 6–12 | Y/N | 3390 |
| Malawi | Ashorn 2015 (47) | iLiNS-DYAD-Malawi | 6 | 12 | Y | 664 |
| Malawi | Maleta 2015 (48) | iLiNS-DOSE | 6 | 12 | N | 943 |
| Mali | Huybregts 2019 (35) | PROMIS-Mali | 6 | 18 | N | 2937 |
| Zimbabwe | Humphrey 2019 (33) | SHINE | 6 | 12 | N | 3676 |
| Zimbabwe | Prendergast 2019 (34) | SHINE (HIV-exposed) | 6 | 12 | N | 667 |
1IPD, individual participant data; LNS, lipid-based nutrient supplement; N, no; PROMIS, Innovative Approaches for the Prevention of Childhood Malnutrition; RDNS, Rang-Din Nutrition Study; SHINE, Sanitation, Hygiene, Infant Nutrition Efficacy Project; SQ-LNS, small-quantity lipid-based nutrient supplement; Y, yes; Y/N indicates that the trial had at least one arm with maternal LNSs + child LNSs and at least one arm with child LNSs only.